Drug Trial Radar · NCT01243177
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
888
Actual
Start
Apr 2011
Primary completion
Jul 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- UCB BIOSCIENCES GmbHUCB
- Sponsor type
- Industry
- Collaborators
- Eden Sarl
- First posted
- Nov 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).
Conditions
- Epilepsy
- Monotherapy
Interventions
LacosamideDrug
Lacosamide: * Strengths: 50 mg / 100 mg * Form: tablets * Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose * Duration: up to 118 weeks
Carbamazepine-Controlled ReleaseDrug
Carbamazepine-CR: * Strengths: 200 mg * Form: tablets * Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose * Duration: up to 118 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects in the Full Analysis Set (FAS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the Last Evaluated Dose for Each SubjectTime frame: 6 consecutive months (26 consecutive weeks) of treatment following stabilization at the last evaluated dose for each subject
- Proportion of Subjects in the Per Protocol Set (PPS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the Last Evaluated Dose for Each SubjectTime frame: 6 consecutive months (26 consecutive weeks) of treatment
- Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)
- Number of Subjects Who Withdraw From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)
- Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)
Locations
184 sites in 29 countries. Site status is shown where the registry gives one.
786
Alabaster, Alabama
799
Huntsville, Alabama
780
Phoenix, Arizona
777
Little Rock, Arkansas
795
Ocala, Florida
789
Panama City, Florida
776
Port Charlotte, Florida
779
Manhattan, Kansas
874
Charlotte, North Carolina
876
Hickory, North Carolina
873
Raleigh, North Carolina
794
Oklahoma City, Oklahoma
881
Mansfield, Texas
790
Madison, Wisconsin
798
Casper, Wyoming
104
Chatswood, Australia
105
Clayton, Australia
106
East Gosford, New South Wales, Australia
109
Randwick, New South Wales, Australia
102
Westmead, New South Wales, Australia
103
Herston, Queensland, Australia
100
Woodville, South Australia, Australia
101
Fitzroy, Victoria, Australia
108
Heidelberg, Victoria, Australia
127
Bruges, Belgium
134
Bruges, Belgium
128
Hasselt, Belgium
126
Leuven, Belgium
805
Blagoevgrad, Bulgaria
807
Panagyurishte, Bulgaria
803
Pleven, Bulgaria
810
Rousse, Bulgaria
806
Sofia, Bulgaria
808
Sofia, Bulgaria
811
Sofia, Bulgaria
809
Veliko Tarnovo, Bulgaria
155
Calgary, Canada
158
Halifax Nova Scotia, Canada
156
Hamilton, Canada
159
Veilleux, Canada
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.